panzyga® - Human Immunoglobulin Intravenous
panzyga® leverages a state-of-the-art manufacturing process that delivers confidence for healthcare professionals, patients and caregivers..1-3
When medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.1
Our production process explained in a short video
panzyga® is part of our commitment which drives us to expand our treatment solutions for healthcare professionals and patients.
panzyga® has been designed to deliver an optimal treatment experience based on efficacy, convenience of administration, safety and tolerability..4-7
panzyga® can make a difference for healthcare professionals, patients and caregivers by providing a range of support resources during the treatment journey. You can look to the future and beyond the condition with confidence.
References
* PSAF=failure to mount at least a 2-fold rise in immunoglobulin G antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines.
Panzyga® Summary of Product Characteristics.
Mersich C, Ahrer K, Buchacher A, Ernegger T, Kohla G, Kannicht C, Pock K, Römisch J. Biochemical characterization and stability of immune globulin intravenous 10% liquid (Panzyga®). Biologicals. 2017 Jan;45:33-38. doi: 10.1016/j.biologicals.2016.10.003. Epub 2016 Oct 27. PMID: 28341308. [PubMed]
Radomski KU, Lattner G, Schmidt T, Römisch J. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid. BioDrugs. 2017 Apr;31(2):125-134. doi: 10.1007/s40259-017-0212-y. PMID: 28236170; PMCID: PMC5380692. [PubMed]
Borte M, Melamed IR, Pulka G, Pyringer B, Knutsen AP, Ochs HD, Kobayashi RH, Kobayashi AL, Gupta S, Strach M, Smits W, Pituch-Noworolska A, Moy JN. Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. J Clin Immunol. 2017 Aug;37(6):603-612. doi: 10.1007/s10875-017-0424-4. Epub 2017 Jul 29. PMID: 28755067; PMCID: PMC5554470. [PubMed]
Arbach O, Taumberger AB, Wietek S, Cervinek L, Salama A. Efficacy and safety of a new intravenous immunoglobulin (Panzyga® ) in chronic immune thrombocytopenia. Transfus Med. 2019 Feb;29(1):48-54. doi: 10.1111/tme.12573. Epub 2019 Jan 27. PMID: 30687970; PMCID: PMC6850321. [PubMed]
Cornblath DR, van Doorn PA, Hartung HP, Merkies ISJ, Katzberg HD, Hinterberger D, Clodi E; ProCID Investigators. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022 Apr 29;145(3):887-896. doi: 10.1093/brain/awab422. PMID: 35038723; PMCID: PMC9050528. [PubMed]
Ochs HD, Melamed I, Borte M, Moy JN, Pyringer B, D Kobayashi AL, Knutsen AP, Smits W, Pituch-Noworolska A, Kobayashi RH. Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. Immunotherapy. 2018 Oct;10(14):1193-1202. doi: 10.2217/imt-2018-0074. Epub 2018 Aug 8. PMID: 30088423. [PubMed]
